Biomed to build plasma fraction plant

The Polish pharmaceutical company will invest PLN 234.5 million and apply for a PLN 100 million public and credit funding in order to establish the Plasma Fractionation Plant in Mielec (Podkarpackie), the firm’s CEO Waldemar Sierocki informed. Biomed is going to apply for PARP (the Polish Agency for Enterprise Development) grant and a trade credit. It is also considering issuing of shares, according to the CEO. "We would like to be the only plasma fractionation company in Poland…Plasma has been imported to Poland by now," Sierocki said. Manufacturing of plasma is to launch in mid-2016. Biomed-Lublin Serum and Vaccine Production Plant has been manufacturing medicinal products, medical devices and laboratory reagents since 1944. It debuted on the WSE on Friday (January 30).